Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: Results from a six-month prospective, multinational, observational study
Authors:
- 1 January 2009
- journal article
- research article
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 10 (4-3) , 729-740
Abstract
The aim of this 6-month observational study was to examine which clinical, eating- and lifestyle-related factors were associated with weight gain in patients initiating or switching to oral olanzapine for the treatment of schizophrenia or bipolar mania. A total of 622 outpatients in four countries (China, Mexico, Romania, Taiwan) were assessed at monthly intervals for up to 6 months. Mixed model repeated-measures analysis, adjusted for baseline weight, was used to identify which factors were associated with weight gain during olanzapine therapy. After 6 months of therapy, the LS mean weight change was +4.1 kg and 43.9% of the patients had significant (≥7%) weight gain. Early significant weight gain after 2 months of therapy occurred in 23.4% of the patients and these patients gained significantly more weight overall. Ten factors were associated with weight gain during 6 months of olanzapine therapy in an exploratory multivariate analysis: country, housing conditions, stronger appetite, excessive amount of food needed to feel full, eating until uncomfortably full, thoughts preoccupied with food, meal location, increased meal frequency, evening snack consumption, and a lower amount of vigorous exercise. These results indicate that the influence of environmental, eating- and lifestyle-related factors should be considered when assessing weight gain during olanzapine therapy.Keywords
This publication has 23 references indexed in Scilit:
- Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorderBMC Psychiatry, 2008
- A Psychoeducational Program for Weight Loss in Patients who have Experienced Weight Gain during Antipsychotic Treatment with OlanzapinePharmacopsychiatry, 2008
- Antipsychotic Induced Weight Gain in Schizophrenia: Mechanisms and ManagementAustralian & New Zealand Journal of Psychiatry, 2008
- Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled studyPsychopharmacology, 2007
- Adverse Effects of Atypical AntipsychoticsCNS Drugs, 2007
- Early Predictors of Substantial Weight Gain in Bipolar Patients Treated with OlanzapineJournal of Clinical Psychopharmacology, 2006
- Weight Management Program for Treatment-Emergent Weight Gain in Olanzapine-Treated Patients With Schizophrenia or Schizoaffective DisorderThe Journal of Clinical Psychiatry, 2006
- Obesity and Related Metabolic Abnormalities during Antipsychotic Drug Administration: Mechanisms, Management and Research PerspectivesPharmacopsychiatry, 2002
- Weight Gain Associated With Increased Food Intake and Low Habitual Activity Levels in Male Adolescent Schizophrenic Inpatients Treated With OlanzapineAmerican Journal of Psychiatry, 2002
- Long-Term Olanzapine TreatmentThe Journal of Clinical Psychiatry, 2001